Unicyte Shares Plunge 39% on Lead Therapy Approval Delay
UNCY•Shares of Unicyte Pharmaceuticals plunged 39% in a single session after the FDA deferred its lead therapy’s approval by 5 to 12 months. Analysts retained buy recommendations, citing the drug’s long-term market potential despite the extended review timeline.
1. Lead Therapy Approval Delay
The FDA notified Unicyte Pharmaceuticals that its flagship investigational therapy will face an additional 5 to 12 months of review, extending the original approval timeline due to requests for supplementary clinical data and manufacturing details.
2. Stock Reaction
Following the announcement, Unicyte shares tumbled 39% in one trading day, marking the company’s steepest decline over the past year as investors adjusted expectations for near-term commercialization.
3. Analyst Perspectives
Despite the setback, multiple brokerage firms reaffirmed buy ratings, emphasizing the therapy’s differentiated clinical profile, large addressable patient population, and potential for significant revenue once regulatory approval is secured.
